These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 38715326)

  • 21. Zingiberene, a non-zinc-binding class I HDAC inhibitor: A novel strategy for the management of neuropathic pain.
    Borgonetti V; Governa P; Manetti F; Galeotti N
    Phytomedicine; 2023 Mar; 111():154670. PubMed ID: 36681053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders.
    Gupta R; Ambasta RK; Kumar P
    Life Sci; 2020 Feb; 243():117278. PubMed ID: 31926248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
    Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting histone deacetylase in thyroid cancer.
    Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
    Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
    Miller CP; Singh MM; Rivera-Del Valle N; Manton CA; Chandra J
    J Biomed Biotechnol; 2011; 2011():514261. PubMed ID: 21765634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone Deacetylase Inhibitors and Diabetic Kidney Disease.
    Hadden MJ; Advani A
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30189630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylases as targets in autoimmune and autoinflammatory diseases.
    Hamminger P; Rica R; Ellmeier W
    Adv Immunol; 2020; 147():1-59. PubMed ID: 32981634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
    Bai Y; Ahmad D; Wang T; Cui G; Li W
    Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HDAC inhibitors restore C-fibre sensitivity in experimental neuropathic pain model.
    Matsushita Y; Araki K; Omotuyi Oi; Mukae T; Ueda H
    Br J Pharmacol; 2013 Nov; 170(5):991-8. PubMed ID: 24032674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain.
    Denk F; Huang W; Sidders B; Bithell A; Crow M; Grist J; Sharma S; Ziemek D; Rice ASC; Buckley NJ; McMahon SB
    Pain; 2013 Sep; 154(9):1668-1679. PubMed ID: 23693161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
    Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
    Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-histone substrates of histone deacetylases as potential therapeutic targets in epilepsy.
    Kumar S; Attrish D; Srivastava A; Banerjee J; Tripathi M; Chandra PS; Dixit AB
    Expert Opin Ther Targets; 2021 Jan; 25(1):75-85. PubMed ID: 33275850
    [No Abstract]   [Full Text] [Related]  

  • 33. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
    Christianson DW
    Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
    Ganai SA
    Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells.
    Zhang S; Zhan L; Li X; Yang Z; Luo Y; Zhao H
    Int J Biol Sci; 2021; 17(13):3381-3400. PubMed ID: 34512154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
    Korfei M; Mahavadi P; Guenther A
    Cells; 2022 May; 11(10):. PubMed ID: 35626663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone Deacetylase Inhibitors as Cognitive Enhancers and Modifiers of Mood and Behavior.
    Pal D; Sahu P; Mishra AK; Hagelgans A; Sukocheva O
    Curr Drug Targets; 2023; 24(9):728-750. PubMed ID: 36475351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suberoylanilide Hydroxamic Acid Triggers Autophagy by Influencing the mTOR Pathway in the Spinal Dorsal Horn in a Rat Neuropathic Pain Model.
    Feng XL; Deng HB; Wang ZG; Wu Y; Ke JJ; Feng XB
    Neurochem Res; 2019 Feb; 44(2):450-464. PubMed ID: 30560396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone Deacetylase Modifications by Probiotics in Colorectal Cancer.
    Salek Farrokhi A; Mohammadlou M; Abdollahi M; Eslami M; Yousefi B
    J Gastrointest Cancer; 2020 Sep; 51(3):754-764. PubMed ID: 31808058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.